Umoja Biopharma develops an in vivo CAR T-cell gene therapy platform that reprograms the immune system to target solid tumors and hematological cancers resistant to current treatments. This approach aims to achieve durable remissions in patients by enhancing the body's natural ability to fight cancer.
Funding
$371M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DBDPFounders
Product
Problem
Current cancer treatments, including immunotherapies, often fail to provide durable remissions for patients with solid tumors and hematological cancers. Many patients do not respond adequately, and resistance to existing therapies can develop over time.
Solution
Umoja Biopharma is developing an *in vivo* CAR T-cell gene therapy platform designed to reprogram the patient's own immune system to target and eliminate cancer cells directly within the body. This approach aims to overcome the limitations of existing immunotherapies by enhancing the body's natural ability to fight cancer and generate lasting remissions, particularly in cancers that are poorly responsive to current treatments. The platform is designed to be scalable and applicable to both solid tumors and hematologic malignancies.
Target Audience
The primary target audience includes patients with solid tumors and hematological cancers that are resistant or poorly responsive to existing immunotherapies, as well as the physicians who treat them.
Features
- *In vivo* CAR T-cell generation, reprogramming T cells directly within the patient's body.
- Integrated therapeutic platform designed to target cancer cells and generate lasting remissions.
- Scalable therapeutic regimens suitable for treating solid tumors and hematological cancers.
- Off-the-shelf CAR T-cell gene therapy platform.